Clinical Trials Logo

Clinical Trial Summary

Hand functions are decreased in rheumatic diseases such as systemic sclerosis and rheumatoid arthritis. Sjögren's syndrome (SS) is a chronic systemic rheumatic disease characterized by lymphoplasmacytic infiltration of exocrine glands, especially salivary and lacrimal glands. SS may be "primary" when it occurs alone (pSS) and "secondary" (sSS) when associated with another autoimmune disease. PSS is the most common connective tissue disease after rheumatoid arthritis and affects 0.3-3% of the population. Joint involvement is the most common involvement of pSS after sicca syndrome (50% of patients). Patients may have arthralgia with inflammatory features (morning stiffness > 30 minutes) or, less frequently, true symmetric polysynovitis mimicking rheumatoid arthritis (RA). The joint involvement of PSS is usually moderate (<5 affected joints) and mostly affects the small joints of the hands and upper extremities. PSS may also be responsible for myositis. Widespread pain, similar to primary fibromyalgia, is common in about 50 percent of patients with PSS. The hand is one of the most important components affecting the functionality of the upper extremity. Grasping is one of the hand functions, for the continuity of daily living activities. is an important function. Studies have shown that hand grip strength is correlated with upper extremity muscle strength, as well as general body muscle strength and pulmonary muscle strength. As far as we know, hand functions have not been evaluated in newly diagnosed patients with pSS.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05115487
Study type Observational
Source Selcuk University
Contact Suleyman AKGOL
Phone +90332 241 50 00
Email slmakgol07@gmail.com
Status Recruiting
Phase
Start date October 15, 2021
Completion date May 7, 2023

See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Active, not recruiting NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT06104124 - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3
Recruiting NCT05383677 - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT00565526 - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2
Recruiting NCT03953703 - Levocarnitine for Dry Eye in Sjogren's Syndrome Phase 2